#METABOLOMICS WORKBENCH NReisdorphLab_20190710_171348 DATATRACK_ID:1768 STUDY_ID:ST001217 ANALYSIS_ID:AN002030 PROJECT_ID:PR000817
VERSION             	1
CREATED_ON             	July 17, 2019, 8:43 am
#PROJECT
PR:PROJECT_TITLE                 	COPD Matched Lavage and Plasma
PR:PROJECT_SUMMARY               	Matched BAL and plasma from 115 COPD subjects from the SPIROMICS cohort were
PR:PROJECT_SUMMARY               	analyzed using untargeted LCMS metabolomics
PR:INSTITUTE                     	University of Colorado Anschutz Medical Campus & National Jewish Health
PR:LAST_NAME                     	Reisdorph
PR:FIRST_NAME                    	Nichole
PR:ADDRESS                       	12850 E Montview Blvd
PR:EMAIL                         	Nichole.Reisdorph@cuanschutz.edu
PR:PHONE                         	303-742-9234
#STUDY
ST:STUDY_TITLE                   	LCMS untargeted Plasma analysis from COPD subjects
ST:STUDY_SUMMARY                 	To use LCMS untargeted metabolomics for the purpose of detecting metabolites in
ST:STUDY_SUMMARY                 	115 matched BAL and plasma that are associated with COPD
ST:INSTITUTE                     	University of Colorado & National Jewish Health
ST:LAST_NAME                     	Reisdorph
ST:FIRST_NAME                    	Nichole
ST:ADDRESS                       	12850 E Montview Blvd
ST:EMAIL                         	Nichole.Reisdorph@cuanschutz.edu
ST:PHONE                         	303-720-9234
#SUBJECT
SU:SUBJECT_TYPE                  	Human
SU:SUBJECT_SPECIES               	Homo sapiens
SU:TAXONOMY_ID                   	9606
SU:GENDER                        	Male and female
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data
SUBJECT_SAMPLE_FACTORS           	-	Plasma_01	GOLD_STAGE_COPD_SEVERITY:1	PCT_POST_FEV1_V1=96.400444; POST_FEV1FVC_DERV=0.8067362; SITE=CU100096; BMI_CM01=25.3; GENDER=2; RACE=3; AGE_DERV_01=52; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=4.307; CBC_LYMPHOCYTE_CNT01=2.336; CBC_MONOCYTE_CNT01=0.292; CBC_EOSINOPHIL_CNT01=0.365; CBC_BASOPHIL_CNT01=0.073; SMOKING_PACK_YEARS01=-; BASELINE_ASTHMA_DX=-; CBC04_DERV=12.2; CBC05_DERV=38.8; CBC14_DERV=349
SUBJECT_SAMPLE_FACTORS           	-	Plasma_02	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=87.14753; POST_FEV1FVC_DERV=0.80034584; SITE=CU100361; BMI_CM01=25.5; GENDER=2; RACE=2; AGE_DERV_01=44; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=No; CBC_NEUTROPHIL_CNT01=3.752; CBC_LYMPHOCYTE_CNT01=2.412; CBC_MONOCYTE_CNT01=0.335; CBC_EOSINOPHIL_CNT01=0.201; CBC_BASOPHIL_CNT01=0.067; SMOKING_PACK_YEARS01=23; BASELINE_ASTHMA_DX=-; CBC04_DERV=13; CBC05_DERV=39.7; CBC14_DERV=371
SUBJECT_SAMPLE_FACTORS           	-	Plasma_03	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=101.46793; POST_FEV1FVC_DERV=0.8018862; SITE=CU100394; BMI_CM01=25.1; GENDER=1; RACE=1; AGE_DERV_01=50; PEX_TOT0101=1; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=1; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=1.845; CBC_LYMPHOCYTE_CNT01=1.599; CBC_MONOCYTE_CNT01=0.451; CBC_EOSINOPHIL_CNT01=0.123; CBC_BASOPHIL_CNT01=0.041; SMOKING_PACK_YEARS01=22; BASELINE_ASTHMA_DX=1; CBC04_DERV=14.5; CBC05_DERV=42.9; CBC14_DERV=235
SUBJECT_SAMPLE_FACTORS           	-	Plasma_04	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=97.819405; POST_FEV1FVC_DERV=0.76253814; SITE=CU102027; BMI_CM01=37; GENDER=1; RACE=1; AGE_DERV_01=59; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=1; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=2.99; CBC_LYMPHOCYTE_CNT01=3.17; CBC_MONOCYTE_CNT01=0.5; CBC_EOSINOPHIL_CNT01=0.14; CBC_BASOPHIL_CNT01=0.02; SMOKING_PACK_YEARS01=73.5; BASELINE_ASTHMA_DX=-; CBC04_DERV=14.2; CBC05_DERV=42.9; CBC14_DERV=224
SUBJECT_SAMPLE_FACTORS           	-	Plasma_05	GOLD_STAGE_COPD_SEVERITY:1	PCT_POST_FEV1_V1=90.28214; POST_FEV1FVC_DERV=0.8667902; SITE=CU102055; BMI_CM01=20.7; GENDER=2; RACE=2; AGE_DERV_01=41; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=No; CBC_NEUTROPHIL_CNT01=1.35; CBC_LYMPHOCYTE_CNT01=1.02; CBC_MONOCYTE_CNT01=0.13; CBC_EOSINOPHIL_CNT01=0.03; CBC_BASOPHIL_CNT01=0.02; SMOKING_PACK_YEARS01=-; BASELINE_ASTHMA_DX=-; CBC04_DERV=10.6; CBC05_DERV=31.7; CBC14_DERV=321
SUBJECT_SAMPLE_FACTORS           	-	Plasma_06	GOLD_STAGE_COPD_SEVERITY:1	PCT_POST_FEV1_V1=111.259; POST_FEV1FVC_DERV=0.9010157; SITE=CU102349; BMI_CM01=30.7; GENDER=2; RACE=1; AGE_DERV_01=57; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=1; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=2.74; CBC_LYMPHOCYTE_CNT01=1.29; CBC_MONOCYTE_CNT01=0.38; CBC_EOSINOPHIL_CNT01=0.01; CBC_BASOPHIL_CNT01=0.02; SMOKING_PACK_YEARS01=-; BASELINE_ASTHMA_DX=-; CBC04_DERV=12.6; CBC05_DERV=38.1; CBC14_DERV=297
SUBJECT_SAMPLE_FACTORS           	-	Plasma_07	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=92.03431; POST_FEV1FVC_DERV=0.7270642; SITE=CU102883; BMI_CM01=33.7; GENDER=2; RACE=6; AGE_DERV_01=44; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=No; CBC_NEUTROPHIL_CNT01=6.89; CBC_LYMPHOCYTE_CNT01=2.08; CBC_MONOCYTE_CNT01=0.58; CBC_EOSINOPHIL_CNT01=0.19; CBC_BASOPHIL_CNT01=0.19; SMOKING_PACK_YEARS01=24; BASELINE_ASTHMA_DX=1; CBC04_DERV=11.7; CBC05_DERV=37.6; CBC14_DERV=353
SUBJECT_SAMPLE_FACTORS           	-	Plasma_08	GOLD_STAGE_COPD_SEVERITY:4	PCT_POST_FEV1_V1=46.1642; POST_FEV1FVC_DERV=0.511121; SITE=CU103085; BMI_CM01=27.4; GENDER=1; RACE=1; AGE_DERV_01=55; PEX_TOT0101=1; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=2; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=NA; CBC_LYMPHOCYTE_CNT01=NA; CBC_MONOCYTE_CNT01=NA; CBC_EOSINOPHIL_CNT01=NA; CBC_BASOPHIL_CNT01=NA; SMOKING_PACK_YEARS01=90; BASELINE_ASTHMA_DX=1; CBC04_DERV=NA; CBC05_DERV=NA; CBC14_DERV=NA
SUBJECT_SAMPLE_FACTORS           	-	Plasma_09	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=98.53231; POST_FEV1FVC_DERV=0.62400854; SITE=CU103222; BMI_CM01=22.3; GENDER=1; RACE=2; AGE_DERV_01=64; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=3.6; CBC_LYMPHOCYTE_CNT01=2.39; CBC_MONOCYTE_CNT01=0.61; CBC_EOSINOPHIL_CNT01=0.07; CBC_BASOPHIL_CNT01=0.05; SMOKING_PACK_YEARS01=98; BASELINE_ASTHMA_DX=-; CBC04_DERV=14.8; CBC05_DERV=43.8; CBC14_DERV=288
SUBJECT_SAMPLE_FACTORS           	-	Plasma_10	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=102.51546; POST_FEV1FVC_DERV=0.7132276; SITE=CU103506; BMI_CM01=33.7; GENDER=2; RACE=2; AGE_DERV_01=49; PEX_TOT0101=-; CB_VISIT1=NA; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=6.16; CBC_LYMPHOCYTE_CNT01=1.62; CBC_MONOCYTE_CNT01=0.41; CBC_EOSINOPHIL_CNT01=0.06; CBC_BASOPHIL_CNT01=0.01; SMOKING_PACK_YEARS01=35; BASELINE_ASTHMA_DX=1; CBC04_DERV=13.7; CBC05_DERV=41.9; CBC14_DERV=306
SUBJECT_SAMPLE_FACTORS           	-	Plasma_11	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=99.11264; POST_FEV1FVC_DERV=0.8168287; SITE=CU104176; BMI_CM01=26.6; GENDER=1; RACE=2; AGE_DERV_01=54; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=3.11; CBC_LYMPHOCYTE_CNT01=0.87; CBC_MONOCYTE_CNT01=0.4; CBC_EOSINOPHIL_CNT01=0.07; CBC_BASOPHIL_CNT01=0.01; SMOKING_PACK_YEARS01=38; BASELINE_ASTHMA_DX=-; CBC04_DERV=14.6; CBC05_DERV=45.1; CBC14_DERV=194
SUBJECT_SAMPLE_FACTORS           	-	Plasma_12	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=106.36166; POST_FEV1FVC_DERV=0.86502784; SITE=CU104293; BMI_CM01=25.2; GENDER=1; RACE=1; AGE_DERV_01=46; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=1; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=4.34; CBC_LYMPHOCYTE_CNT01=1.58; CBC_MONOCYTE_CNT01=0.38; CBC_EOSINOPHIL_CNT01=0.24; CBC_BASOPHIL_CNT01=0.03; SMOKING_PACK_YEARS01=27; BASELINE_ASTHMA_DX=1; CBC04_DERV=14.1; CBC05_DERV=42.9; CBC14_DERV=251
SUBJECT_SAMPLE_FACTORS           	-	Plasma_13	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=104.31494; POST_FEV1FVC_DERV=0.8146281; SITE=CU104409; BMI_CM01=29.8; GENDER=2; RACE=1; AGE_DERV_01=52; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=1; BRONCH_DIAGNOSED01=-; MENOPAUSE01=No; CBC_NEUTROPHIL_CNT01=4.17; CBC_LYMPHOCYTE_CNT01=2.16; CBC_MONOCYTE_CNT01=0.61; CBC_EOSINOPHIL_CNT01=0.13; CBC_BASOPHIL_CNT01=0.05; SMOKING_PACK_YEARS01=29.25; BASELINE_ASTHMA_DX=-; CBC04_DERV=13.2; CBC05_DERV=41; CBC14_DERV=325
SUBJECT_SAMPLE_FACTORS           	-	Plasma_14	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=94.68381; POST_FEV1FVC_DERV=0.83201224; SITE=CU104425; BMI_CM01=21.5; GENDER=2; RACE=2; AGE_DERV_01=48; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=1; BRONCH_DIAGNOSED01=-; MENOPAUSE01=No; CBC_NEUTROPHIL_CNT01=4.33; CBC_LYMPHOCYTE_CNT01=1.72; CBC_MONOCYTE_CNT01=0.42; CBC_EOSINOPHIL_CNT01=0.11; CBC_BASOPHIL_CNT01=0.04; SMOKING_PACK_YEARS01=43; BASELINE_ASTHMA_DX=-; CBC04_DERV=12.2; CBC05_DERV=36.9; CBC14_DERV=255
SUBJECT_SAMPLE_FACTORS           	-	Plasma_15	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=89.92103; POST_FEV1FVC_DERV=0.79961836; SITE=CU104486; BMI_CM01=23.9; GENDER=1; RACE=1; AGE_DERV_01=50; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=3.88; CBC_LYMPHOCYTE_CNT01=1.38; CBC_MONOCYTE_CNT01=0.61; CBC_EOSINOPHIL_CNT01=0.11; CBC_BASOPHIL_CNT01=0.04; SMOKING_PACK_YEARS01=25; BASELINE_ASTHMA_DX=-; CBC04_DERV=15.2; CBC05_DERV=45.4; CBC14_DERV=211
SUBJECT_SAMPLE_FACTORS           	-	Plasma_16	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=100.120255; POST_FEV1FVC_DERV=0.79997087; SITE=CU104873; BMI_CM01=30.8; GENDER=2; RACE=2; AGE_DERV_01=45; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=1; BRONCH_DIAGNOSED01=-; MENOPAUSE01=No; CBC_NEUTROPHIL_CNT01=3.36; CBC_LYMPHOCYTE_CNT01=2.77; CBC_MONOCYTE_CNT01=0.36; CBC_EOSINOPHIL_CNT01=0.07; CBC_BASOPHIL_CNT01=0.01; SMOKING_PACK_YEARS01=45; BASELINE_ASTHMA_DX=-; CBC04_DERV=12.5; CBC05_DERV=40; CBC14_DERV=327
SUBJECT_SAMPLE_FACTORS           	-	Plasma_17	GOLD_STAGE_COPD_SEVERITY:1	PCT_POST_FEV1_V1=93.82796; POST_FEV1FVC_DERV=0.8121731; SITE=LA190094; BMI_CM01=24.7; GENDER=2; RACE=1; AGE_DERV_01=60; PEX_TOT0101=1; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=4.2; CBC_LYMPHOCYTE_CNT01=1.7; CBC_MONOCYTE_CNT01=0.3; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=-; BASELINE_ASTHMA_DX=-; CBC04_DERV=14.3; CBC05_DERV=41.6; CBC14_DERV=354
SUBJECT_SAMPLE_FACTORS           	-	Plasma_18	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=70.55727; POST_FEV1FVC_DERV=0.5354953; SITE=LA190221; BMI_CM01=33.4; GENDER=2; RACE=1; AGE_DERV_01=67; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=1; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=4.6; CBC_LYMPHOCYTE_CNT01=2.4; CBC_MONOCYTE_CNT01=0.5; CBC_EOSINOPHIL_CNT01=0.2; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=34; BASELINE_ASTHMA_DX=1; CBC04_DERV=13.2; CBC05_DERV=40; CBC14_DERV=341
SUBJECT_SAMPLE_FACTORS           	-	Plasma_19	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=81.51273; POST_FEV1FVC_DERV=0.7619634; SITE=LA190249; BMI_CM01=37.3; GENDER=2; RACE=2; AGE_DERV_01=59; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=3.9; CBC_LYMPHOCYTE_CNT01=2.3; CBC_MONOCYTE_CNT01=0.6; CBC_EOSINOPHIL_CNT01=0.2; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=45; BASELINE_ASTHMA_DX=-; CBC04_DERV=11.8; CBC05_DERV=36.6; CBC14_DERV=338
SUBJECT_SAMPLE_FACTORS           	-	Plasma_20	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=102.208954; POST_FEV1FVC_DERV=0.6478054; SITE=LA190310; BMI_CM01=31.2; GENDER=1; RACE=1; AGE_DERV_01=69; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=4.5; CBC_LYMPHOCYTE_CNT01=2.1; CBC_MONOCYTE_CNT01=0.7; CBC_EOSINOPHIL_CNT01=0.2; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=25; BASELINE_ASTHMA_DX=-; CBC04_DERV=14; CBC05_DERV=43.2; CBC14_DERV=181
SUBJECT_SAMPLE_FACTORS           	-	Plasma_21	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=87.78327; POST_FEV1FVC_DERV=0.5475062; SITE=LA190563; BMI_CM01=21.9; GENDER=2; RACE=1; AGE_DERV_01=75; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=1; MENOPAUSE01=No; CBC_NEUTROPHIL_CNT01=4.4; CBC_LYMPHOCYTE_CNT01=2; CBC_MONOCYTE_CNT01=0.8; CBC_EOSINOPHIL_CNT01=0.2; CBC_BASOPHIL_CNT01=0.1; SMOKING_PACK_YEARS01=35; BASELINE_ASTHMA_DX=-; CBC04_DERV=13.2; CBC05_DERV=40.4; CBC14_DERV=252
SUBJECT_SAMPLE_FACTORS           	-	Plasma_22	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=93.13102; POST_FEV1FVC_DERV=0.6129999; SITE=LA190657; BMI_CM01=26.5; GENDER=2; RACE=2; AGE_DERV_01=71; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=1; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=1.9; CBC_LYMPHOCYTE_CNT01=3.3; CBC_MONOCYTE_CNT01=0.5; CBC_EOSINOPHIL_CNT01=0.2; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=45; BASELINE_ASTHMA_DX=-; CBC04_DERV=12.7; CBC05_DERV=37.6; CBC14_DERV=280
SUBJECT_SAMPLE_FACTORS           	-	Plasma_23	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=94.31832; POST_FEV1FVC_DERV=0.7219894; SITE=LA190690; BMI_CM01=35.9; GENDER=2; RACE=2; AGE_DERV_01=50; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=2.3; CBC_LYMPHOCYTE_CNT01=2.5; CBC_MONOCYTE_CNT01=0.5; CBC_EOSINOPHIL_CNT01=0.3; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=25; BASELINE_ASTHMA_DX=-; CBC04_DERV=11.9; CBC05_DERV=36.3; CBC14_DERV=279
SUBJECT_SAMPLE_FACTORS           	-	Plasma_24	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=95.84416; POST_FEV1FVC_DERV=0.5869845; SITE=LA190775; BMI_CM01=29.3; GENDER=1; RACE=1; AGE_DERV_01=68; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=1; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=3.2; CBC_LYMPHOCYTE_CNT01=1; CBC_MONOCYTE_CNT01=0.6; CBC_EOSINOPHIL_CNT01=0.3; CBC_BASOPHIL_CNT01=0.1; SMOKING_PACK_YEARS01=30; BASELINE_ASTHMA_DX=1; CBC04_DERV=13.9; CBC05_DERV=43.1; CBC14_DERV=208
SUBJECT_SAMPLE_FACTORS           	-	Plasma_25	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=118.43461; POST_FEV1FVC_DERV=0.78483856; SITE=LA190852; BMI_CM01=23.2; GENDER=1; RACE=1; AGE_DERV_01=67; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=2.5; CBC_LYMPHOCYTE_CNT01=0.7; CBC_MONOCYTE_CNT01=0.6; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=21; BASELINE_ASTHMA_DX=-; CBC04_DERV=13.9; CBC05_DERV=41.5; CBC14_DERV=245
SUBJECT_SAMPLE_FACTORS           	-	Plasma_26	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=100.30806; POST_FEV1FVC_DERV=0.66489536; SITE=LA191364; BMI_CM01=18.6; GENDER=2; RACE=1; AGE_DERV_01=66; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=1; BRONCH_DIAGNOSED01=1; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=3.3; CBC_LYMPHOCYTE_CNT01=1.4; CBC_MONOCYTE_CNT01=0.3; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=41; BASELINE_ASTHMA_DX=-; CBC04_DERV=13.8; CBC05_DERV=41.3; CBC14_DERV=278
SUBJECT_SAMPLE_FACTORS           	-	Plasma_27	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=91.36782; POST_FEV1FVC_DERV=0.6016274; SITE=LA191457; BMI_CM01=29.6; GENDER=1; RACE=3; AGE_DERV_01=72; PEX_TOT0101=NA; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=6.7; CBC_LYMPHOCYTE_CNT01=1.2; CBC_MONOCYTE_CNT01=1; CBC_EOSINOPHIL_CNT01=0.4; CBC_BASOPHIL_CNT01=0.1; SMOKING_PACK_YEARS01=66; BASELINE_ASTHMA_DX=-; CBC04_DERV=14.1; CBC05_DERV=42.4; CBC14_DERV=307
SUBJECT_SAMPLE_FACTORS           	-	Plasma_28	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=90.70973; POST_FEV1FVC_DERV=0.7346608; SITE=LA191578; BMI_CM01=25.1; GENDER=2; RACE=2; AGE_DERV_01=50; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=3.6; CBC_LYMPHOCYTE_CNT01=4; CBC_MONOCYTE_CNT01=0.6; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=25.5; BASELINE_ASTHMA_DX=-; CBC04_DERV=12; CBC05_DERV=36.5; CBC14_DERV=359
SUBJECT_SAMPLE_FACTORS           	-	Plasma_29	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=99.8934; POST_FEV1FVC_DERV=0.8199858; SITE=LA191580; BMI_CM01=31.8; GENDER=1; RACE=2; AGE_DERV_01=50; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=2.9; CBC_LYMPHOCYTE_CNT01=1.4; CBC_MONOCYTE_CNT01=0.4; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=22.5; BASELINE_ASTHMA_DX=-; CBC04_DERV=14.3; CBC05_DERV=42.4; CBC14_DERV=236
SUBJECT_SAMPLE_FACTORS           	-	Plasma_30	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=76.892494; POST_FEV1FVC_DERV=0.6933033; SITE=LA191996; BMI_CM01=33.1; GENDER=1; RACE=1; AGE_DERV_01=67; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=4.7; CBC_LYMPHOCYTE_CNT01=2.1; CBC_MONOCYTE_CNT01=0.6; CBC_EOSINOPHIL_CNT01=0.5; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=52.5; BASELINE_ASTHMA_DX=-; CBC04_DERV=14.7; CBC05_DERV=43.7; CBC14_DERV=365
SUBJECT_SAMPLE_FACTORS           	-	Plasma_31	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=107.012; POST_FEV1FVC_DERV=0.7410066; SITE=LA192038; BMI_CM01=32.7; GENDER=2; RACE=1; AGE_DERV_01=65; PEX_TOT0101=1; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=1; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=6.2; CBC_LYMPHOCYTE_CNT01=1.8; CBC_MONOCYTE_CNT01=0.4; CBC_EOSINOPHIL_CNT01=0.3; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=75; BASELINE_ASTHMA_DX=1; CBC04_DERV=12.1; CBC05_DERV=36.4; CBC14_DERV=299
SUBJECT_SAMPLE_FACTORS           	-	Plasma_32	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=111.42923; POST_FEV1FVC_DERV=0.6940856; SITE=LA192176; BMI_CM01=24.4; GENDER=1; RACE=1; AGE_DERV_01=64; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=3.3; CBC_LYMPHOCYTE_CNT01=1.6; CBC_MONOCYTE_CNT01=0.6; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=37; BASELINE_ASTHMA_DX=-; CBC04_DERV=14.2; CBC05_DERV=41.8; CBC14_DERV=219
SUBJECT_SAMPLE_FACTORS           	-	Plasma_33	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=97.06062; POST_FEV1FVC_DERV=0.7815941; SITE=LA192259; BMI_CM01=28.6; GENDER=1; RACE=1; AGE_DERV_01=74; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=3.9; CBC_LYMPHOCYTE_CNT01=2.5; CBC_MONOCYTE_CNT01=0.6; CBC_EOSINOPHIL_CNT01=0.2; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=56; BASELINE_ASTHMA_DX=-; CBC04_DERV=14.2; CBC05_DERV=41.1; CBC14_DERV=244
SUBJECT_SAMPLE_FACTORS           	-	Plasma_34	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=110.76649; POST_FEV1FVC_DERV=0.80028284; SITE=LA192486; BMI_CM01=24.9; GENDER=1; RACE=6; AGE_DERV_01=67; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=3.2; CBC_LYMPHOCYTE_CNT01=1.6; CBC_MONOCYTE_CNT01=0.4; CBC_EOSINOPHIL_CNT01=-; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=26.25; BASELINE_ASTHMA_DX=-; CBC04_DERV=14.1; CBC05_DERV=41.2; CBC14_DERV=157
SUBJECT_SAMPLE_FACTORS           	-	Plasma_35	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=96.32796; POST_FEV1FVC_DERV=0.8799544; SITE=LA192596; BMI_CM01=37.2; GENDER=2; RACE=1; AGE_DERV_01=67; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=1.8; CBC_LYMPHOCYTE_CNT01=1.8; CBC_MONOCYTE_CNT01=0.5; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=30.75; BASELINE_ASTHMA_DX=1; CBC04_DERV=13.5; CBC05_DERV=40.4; CBC14_DERV=162
SUBJECT_SAMPLE_FACTORS           	-	Plasma_36	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=121.49806; POST_FEV1FVC_DERV=0.7394778; SITE=LA192611; BMI_CM01=30.7; GENDER=2; RACE=2; AGE_DERV_01=67; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=1.8; CBC_LYMPHOCYTE_CNT01=2.1; CBC_MONOCYTE_CNT01=0.3; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=30; BASELINE_ASTHMA_DX=-; CBC04_DERV=13.7; CBC05_DERV=41.4; CBC14_DERV=234
SUBJECT_SAMPLE_FACTORS           	-	Plasma_37	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=95.269554; POST_FEV1FVC_DERV=0.75301003; SITE=LA192678; BMI_CM01=31.4; GENDER=1; RACE=1; AGE_DERV_01=66; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=1; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=2.4; CBC_LYMPHOCYTE_CNT01=2.4; CBC_MONOCYTE_CNT01=0.5; CBC_EOSINOPHIL_CNT01=0.2; CBC_BASOPHIL_CNT01=0.1; SMOKING_PACK_YEARS01=36; BASELINE_ASTHMA_DX=-; CBC04_DERV=14.9; CBC05_DERV=41.1; CBC14_DERV=240
SUBJECT_SAMPLE_FACTORS           	-	Plasma_38	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=120.74064; POST_FEV1FVC_DERV=0.8027865; SITE=LA192743; BMI_CM01=29.2; GENDER=2; RACE=1; AGE_DERV_01=71; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=4.1; CBC_LYMPHOCYTE_CNT01=1.4; CBC_MONOCYTE_CNT01=0.8; CBC_EOSINOPHIL_CNT01=0.3; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=33; BASELINE_ASTHMA_DX=-; CBC04_DERV=13.2; CBC05_DERV=39.4; CBC14_DERV=326
SUBJECT_SAMPLE_FACTORS           	-	Plasma_39	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=92.678825; POST_FEV1FVC_DERV=0.8283569; SITE=LA192834; BMI_CM01=34.4; GENDER=2; RACE=2; AGE_DERV_01=41; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=No; CBC_NEUTROPHIL_CNT01=1.8; CBC_LYMPHOCYTE_CNT01=1.4; CBC_MONOCYTE_CNT01=0.3; CBC_EOSINOPHIL_CNT01=-; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=24; BASELINE_ASTHMA_DX=-; CBC04_DERV=14.2; CBC05_DERV=42.5; CBC14_DERV=366
SUBJECT_SAMPLE_FACTORS           	-	Plasma_40	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=55.604805; POST_FEV1FVC_DERV=0.40298077; SITE=LA192950; BMI_CM01=28.6; GENDER=2; RACE=1; AGE_DERV_01=66; PEX_TOT0101=2; CB_VISIT1=-; CURRENT_SMOKER_V1=1; BRONCH_DIAGNOSED01=1; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=4.6; CBC_LYMPHOCYTE_CNT01=2.1; CBC_MONOCYTE_CNT01=0.9; CBC_EOSINOPHIL_CNT01=0.2; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=38.25; BASELINE_ASTHMA_DX=1; CBC04_DERV=14; CBC05_DERV=41.7; CBC14_DERV=308
SUBJECT_SAMPLE_FACTORS           	-	Plasma_41	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=105.91159; POST_FEV1FVC_DERV=0.81388986; SITE=LV200185; BMI_CM01=34; GENDER=1; RACE=2; AGE_DERV_01=56; PEX_TOT0101=2; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=4; CBC_LYMPHOCYTE_CNT01=2.2; CBC_MONOCYTE_CNT01=0.6; CBC_EOSINOPHIL_CNT01=0.4; CBC_BASOPHIL_CNT01=0.1; SMOKING_PACK_YEARS01=20; BASELINE_ASTHMA_DX=1; CBC04_DERV=14.7; CBC05_DERV=43.1; CBC14_DERV=304
SUBJECT_SAMPLE_FACTORS           	-	Plasma_42	GOLD_STAGE_COPD_SEVERITY:1	PCT_POST_FEV1_V1=101.95946; POST_FEV1FVC_DERV=0.8938317; SITE=MU160181; BMI_CM01=38.8; GENDER=2; RACE=3; AGE_DERV_01=40; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=No; CBC_NEUTROPHIL_CNT01=5.2; CBC_LYMPHOCYTE_CNT01=2.9; CBC_MONOCYTE_CNT01=0.7; CBC_EOSINOPHIL_CNT01=0.2; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=-; BASELINE_ASTHMA_DX=1; CBC04_DERV=12.7; CBC05_DERV=36.8; CBC14_DERV=308
SUBJECT_SAMPLE_FACTORS           	-	Plasma_43	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=66.3558; POST_FEV1FVC_DERV=0.56357306; SITE=MU160459; BMI_CM01=36.4; GENDER=1; RACE=4; AGE_DERV_01=58; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=1; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=4.1; CBC_LYMPHOCYTE_CNT01=2.3; CBC_MONOCYTE_CNT01=1.3; CBC_EOSINOPHIL_CNT01=0.3; CBC_BASOPHIL_CNT01=0.1; SMOKING_PACK_YEARS01=45; BASELINE_ASTHMA_DX=NA; CBC04_DERV=16.9; CBC05_DERV=47.5; CBC14_DERV=247
SUBJECT_SAMPLE_FACTORS           	-	Plasma_44	GOLD_STAGE_COPD_SEVERITY:1	PCT_POST_FEV1_V1=94.28819; POST_FEV1FVC_DERV=0.91068673; SITE=MU160610; BMI_CM01=25.9; GENDER=2; RACE=2; AGE_DERV_01=46; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=No; CBC_NEUTROPHIL_CNT01=3.9; CBC_LYMPHOCYTE_CNT01=1.6; CBC_MONOCYTE_CNT01=0.5; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=-; BASELINE_ASTHMA_DX=-; CBC04_DERV=12.7; CBC05_DERV=35.9; CBC14_DERV=213
SUBJECT_SAMPLE_FACTORS           	-	Plasma_45	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=108.77168; POST_FEV1FVC_DERV=0.7107612; SITE=MU160696; BMI_CM01=30.4; GENDER=1; RACE=1; AGE_DERV_01=56; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=4.5; CBC_LYMPHOCYTE_CNT01=1.5; CBC_MONOCYTE_CNT01=0.7; CBC_EOSINOPHIL_CNT01=0.5; CBC_BASOPHIL_CNT01=0.1; SMOKING_PACK_YEARS01=32; BASELINE_ASTHMA_DX=-; CBC04_DERV=14.6; CBC05_DERV=42; CBC14_DERV=262
SUBJECT_SAMPLE_FACTORS           	-	Plasma_46	GOLD_STAGE_COPD_SEVERITY:1	PCT_POST_FEV1_V1=98.76818; POST_FEV1FVC_DERV=0.80633044; SITE=MU160730; BMI_CM01=29.4; GENDER=1; RACE=1; AGE_DERV_01=56; PEX_TOT0101=1; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=1; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=2.1; CBC_LYMPHOCYTE_CNT01=2; CBC_MONOCYTE_CNT01=0.4; CBC_EOSINOPHIL_CNT01=0.2; CBC_BASOPHIL_CNT01=0.1; SMOKING_PACK_YEARS01=NA; BASELINE_ASTHMA_DX=1; CBC04_DERV=14.6; CBC05_DERV=40.5; CBC14_DERV=258
SUBJECT_SAMPLE_FACTORS           	-	Plasma_47	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=88.318214; POST_FEV1FVC_DERV=0.83986336; SITE=MU161295; BMI_CM01=31.6; GENDER=1; RACE=2; AGE_DERV_01=56; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=1; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=5; CBC_LYMPHOCYTE_CNT01=1.7; CBC_MONOCYTE_CNT01=0.7; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=30; BASELINE_ASTHMA_DX=-; CBC04_DERV=15.4; CBC05_DERV=45.3; CBC14_DERV=199
SUBJECT_SAMPLE_FACTORS           	-	Plasma_48	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=108.36813; POST_FEV1FVC_DERV=0.8151577; SITE=MU161337; BMI_CM01=34.4; GENDER=1; RACE=1; AGE_DERV_01=52; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=3.8; CBC_LYMPHOCYTE_CNT01=1.3; CBC_MONOCYTE_CNT01=0.5; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=25; BASELINE_ASTHMA_DX=-; CBC04_DERV=16.1; CBC05_DERV=45.1; CBC14_DERV=200
SUBJECT_SAMPLE_FACTORS           	-	Plasma_49	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=108.305695; POST_FEV1FVC_DERV=0.6887248; SITE=MU161509; BMI_CM01=27.4; GENDER=2; RACE=1; AGE_DERV_01=66; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=1; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=2.7; CBC_LYMPHOCYTE_CNT01=1.8; CBC_MONOCYTE_CNT01=0.2; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=0.1; SMOKING_PACK_YEARS01=45; BASELINE_ASTHMA_DX=-; CBC04_DERV=13.8; CBC05_DERV=41.2; CBC14_DERV=258
SUBJECT_SAMPLE_FACTORS           	-	Plasma_50	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=89.69083; POST_FEV1FVC_DERV=0.77797663; SITE=MU161632; BMI_CM01=29.3; GENDER=2; RACE=1; AGE_DERV_01=67; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=1; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=5.4; CBC_LYMPHOCYTE_CNT01=1.5; CBC_MONOCYTE_CNT01=0.6; CBC_EOSINOPHIL_CNT01=0.2; CBC_BASOPHIL_CNT01=0.1; SMOKING_PACK_YEARS01=30; BASELINE_ASTHMA_DX=-; CBC04_DERV=13.4; CBC05_DERV=39.7; CBC14_DERV=242
SUBJECT_SAMPLE_FACTORS           	-	Plasma_51	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=66.45474; POST_FEV1FVC_DERV=0.59906423; SITE=MU161704; BMI_CM01=22.4; GENDER=2; RACE=1; AGE_DERV_01=61; PEX_TOT0101=-; CB_VISIT1=1; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=2.8; CBC_LYMPHOCYTE_CNT01=2; CBC_MONOCYTE_CNT01=0.6; CBC_EOSINOPHIL_CNT01=0.3; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=60; BASELINE_ASTHMA_DX=1; CBC04_DERV=14.1; CBC05_DERV=40.4; CBC14_DERV=229
SUBJECT_SAMPLE_FACTORS           	-	Plasma_52	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=102.78782; POST_FEV1FVC_DERV=0.7390672; SITE=MU162044; BMI_CM01=32.3; GENDER=1; RACE=1; AGE_DERV_01=66; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=1; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=2.8; CBC_LYMPHOCYTE_CNT01=2.2; CBC_MONOCYTE_CNT01=0.6; CBC_EOSINOPHIL_CNT01=0.2; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=90; BASELINE_ASTHMA_DX=-; CBC04_DERV=15.2; CBC05_DERV=45.2; CBC14_DERV=268
SUBJECT_SAMPLE_FACTORS           	-	Plasma_53	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=93.250916; POST_FEV1FVC_DERV=0.6820441; SITE=MU162397; BMI_CM01=36.4; GENDER=2; RACE=1; AGE_DERV_01=64; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=NA; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=2.1; CBC_LYMPHOCYTE_CNT01=1.8; CBC_MONOCYTE_CNT01=0.4; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=0.1; SMOKING_PACK_YEARS01=34; BASELINE_ASTHMA_DX=-; CBC04_DERV=13.5; CBC05_DERV=40.5; CBC14_DERV=343
SUBJECT_SAMPLE_FACTORS           	-	Plasma_54	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=87.64771; POST_FEV1FVC_DERV=0.62910825; SITE=MU162585; BMI_CM01=32.6; GENDER=2; RACE=1; AGE_DERV_01=70; PEX_TOT0101=-; CB_VISIT1=NA; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=2.9; CBC_LYMPHOCYTE_CNT01=1.5; CBC_MONOCYTE_CNT01=0.4; CBC_EOSINOPHIL_CNT01=0.2; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=42; BASELINE_ASTHMA_DX=-; CBC04_DERV=14.7; CBC05_DERV=44.4; CBC14_DERV=291
SUBJECT_SAMPLE_FACTORS           	-	Plasma_55	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=107.311874; POST_FEV1FVC_DERV=0.817478; SITE=MU162776; BMI_CM01=30.4; GENDER=2; RACE=1; AGE_DERV_01=47; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=No; CBC_NEUTROPHIL_CNT01=3.3; CBC_LYMPHOCYTE_CNT01=2.9; CBC_MONOCYTE_CNT01=0.7; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=34.5; BASELINE_ASTHMA_DX=-; CBC04_DERV=13.8; CBC05_DERV=42.2; CBC14_DERV=406
SUBJECT_SAMPLE_FACTORS           	-	Plasma_56	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=88.12051; POST_FEV1FVC_DERV=0.6981962; SITE=MU163030; BMI_CM01=32.6; GENDER=2; RACE=1; AGE_DERV_01=65; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=2.1; CBC_LYMPHOCYTE_CNT01=1.5; CBC_MONOCYTE_CNT01=0.5; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=30; BASELINE_ASTHMA_DX=-; CBC04_DERV=12.2; CBC05_DERV=36.6; CBC14_DERV=261
SUBJECT_SAMPLE_FACTORS           	-	Plasma_57	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=97.17454; POST_FEV1FVC_DERV=0.71186996; SITE=MU163042; BMI_CM01=37; GENDER=1; RACE=1; AGE_DERV_01=67; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=1; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=7.8; CBC_LYMPHOCYTE_CNT01=1.7; CBC_MONOCYTE_CNT01=0.8; CBC_EOSINOPHIL_CNT01=0.3; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=63; BASELINE_ASTHMA_DX=1; CBC04_DERV=14.8; CBC05_DERV=43.3; CBC14_DERV=224
SUBJECT_SAMPLE_FACTORS           	-	Plasma_58	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=84.70521; POST_FEV1FVC_DERV=0.47461417; SITE=MU163116; BMI_CM01=36.4; GENDER=1; RACE=1; AGE_DERV_01=71; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=5.1; CBC_LYMPHOCYTE_CNT01=1.6; CBC_MONOCYTE_CNT01=0.6; CBC_EOSINOPHIL_CNT01=0.4; CBC_BASOPHIL_CNT01=0.1; SMOKING_PACK_YEARS01=112.5; BASELINE_ASTHMA_DX=-; CBC04_DERV=14.5; CBC05_DERV=42.5; CBC14_DERV=259
SUBJECT_SAMPLE_FACTORS           	-	Plasma_59	GOLD_STAGE_COPD_SEVERITY:4	PCT_POST_FEV1_V1=36.28088; POST_FEV1FVC_DERV=0.4154187; SITE=MU163141; BMI_CM01=38.6; GENDER=1; RACE=1; AGE_DERV_01=66; PEX_TOT0101=1; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=1; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=4.9; CBC_LYMPHOCYTE_CNT01=2; CBC_MONOCYTE_CNT01=0.9; CBC_EOSINOPHIL_CNT01=0.3; CBC_BASOPHIL_CNT01=0.1; SMOKING_PACK_YEARS01=85; BASELINE_ASTHMA_DX=-; CBC04_DERV=14.3; CBC05_DERV=44.6; CBC14_DERV=158
SUBJECT_SAMPLE_FACTORS           	-	Plasma_60	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=72.59136; POST_FEV1FVC_DERV=0.6653192; SITE=MU163185; BMI_CM01=28.1; GENDER=1; RACE=1; AGE_DERV_01=64; PEX_TOT0101=1; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=1; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=4.8; CBC_LYMPHOCYTE_CNT01=1.5; CBC_MONOCYTE_CNT01=0.6; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=26.25; BASELINE_ASTHMA_DX=-; CBC04_DERV=15.1; CBC05_DERV=43.8; CBC14_DERV=258
SUBJECT_SAMPLE_FACTORS           	-	Plasma_61	GOLD_STAGE_COPD_SEVERITY:4	PCT_POST_FEV1_V1=44.991943; POST_FEV1FVC_DERV=0.4376311; SITE=MU163497; BMI_CM01=31.4; GENDER=1; RACE=1; AGE_DERV_01=68; PEX_TOT0101=2; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=3.4; CBC_LYMPHOCYTE_CNT01=1.9; CBC_MONOCYTE_CNT01=0.4; CBC_EOSINOPHIL_CNT01=0.2; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=25; BASELINE_ASTHMA_DX=-; CBC04_DERV=18.3; CBC05_DERV=52.4; CBC14_DERV=136
SUBJECT_SAMPLE_FACTORS           	-	Plasma_62	GOLD_STAGE_COPD_SEVERITY:1	PCT_POST_FEV1_V1=107.51474; POST_FEV1FVC_DERV=0.7783386; SITE=MU163526; BMI_CM01=32.5; GENDER=2; RACE=1; AGE_DERV_01=61; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=1; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=3.3; CBC_LYMPHOCYTE_CNT01=1.4; CBC_MONOCYTE_CNT01=0.3; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=-; BASELINE_ASTHMA_DX=-; CBC04_DERV=12.9; CBC05_DERV=40.3; CBC14_DERV=267
SUBJECT_SAMPLE_FACTORS           	-	Plasma_63	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=57.190334; POST_FEV1FVC_DERV=0.4874153; SITE=MU163780; BMI_CM01=27.5; GENDER=2; RACE=1; AGE_DERV_01=67; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=1; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=3.9; CBC_LYMPHOCYTE_CNT01=1.3; CBC_MONOCYTE_CNT01=0.5; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=52.5; BASELINE_ASTHMA_DX=1; CBC04_DERV=12.1; CBC05_DERV=37.2; CBC14_DERV=192
SUBJECT_SAMPLE_FACTORS           	-	Plasma_64	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=85.37649; POST_FEV1FVC_DERV=0.76941127; SITE=MU163925; BMI_CM01=27.7; GENDER=2; RACE=1; AGE_DERV_01=73; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=3.9; CBC_LYMPHOCYTE_CNT01=1.9; CBC_MONOCYTE_CNT01=0.4; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=40; BASELINE_ASTHMA_DX=-; CBC04_DERV=12.9; CBC05_DERV=38.6; CBC14_DERV=361
SUBJECT_SAMPLE_FACTORS           	-	Plasma_65	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=91.286385; POST_FEV1FVC_DERV=0.753718; SITE=MU163961; BMI_CM01=29.3; GENDER=2; RACE=1; AGE_DERV_01=62; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=2.9; CBC_LYMPHOCYTE_CNT01=1.2; CBC_MONOCYTE_CNT01=0.4; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=35.25; BASELINE_ASTHMA_DX=-; CBC04_DERV=12.6; CBC05_DERV=37.7; CBC14_DERV=239
SUBJECT_SAMPLE_FACTORS           	-	Plasma_66	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=66.76122; POST_FEV1FVC_DERV=0.42666432; SITE=MU164021; BMI_CM01=15.8; GENDER=2; RACE=1; AGE_DERV_01=65; PEX_TOT0101=-; CB_VISIT1=1; CURRENT_SMOKER_V1=1; BRONCH_DIAGNOSED01=1; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=6.8; CBC_LYMPHOCYTE_CNT01=2.5; CBC_MONOCYTE_CNT01=0.6; CBC_EOSINOPHIL_CNT01=0.3; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=45; BASELINE_ASTHMA_DX=-; CBC04_DERV=14.4; CBC05_DERV=42.8; CBC14_DERV=275
SUBJECT_SAMPLE_FACTORS           	-	Plasma_67	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=76.93603; POST_FEV1FVC_DERV=0.56149936; SITE=MU164286; BMI_CM01=21.6; GENDER=1; RACE=1; AGE_DERV_01=52; PEX_TOT0101=-; CB_VISIT1=1; CURRENT_SMOKER_V1=1; BRONCH_DIAGNOSED01=1; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=4.4; CBC_LYMPHOCYTE_CNT01=1.2; CBC_MONOCYTE_CNT01=0.4; CBC_EOSINOPHIL_CNT01=0.2; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=30; BASELINE_ASTHMA_DX=-; CBC04_DERV=17.1; CBC05_DERV=48.5; CBC14_DERV=221
SUBJECT_SAMPLE_FACTORS           	-	Plasma_68	GOLD_STAGE_COPD_SEVERITY:4	PCT_POST_FEV1_V1=45.265575; POST_FEV1FVC_DERV=0.5461862; SITE=MU164331; BMI_CM01=22.8; GENDER=2; RACE=1; AGE_DERV_01=41; PEX_TOT0101=2; CB_VISIT1=-; CURRENT_SMOKER_V1=1; BRONCH_DIAGNOSED01=1; MENOPAUSE01=No; CBC_NEUTROPHIL_CNT01=4.3; CBC_LYMPHOCYTE_CNT01=2.4; CBC_MONOCYTE_CNT01=0.5; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=40.5; BASELINE_ASTHMA_DX=1; CBC04_DERV=15; CBC05_DERV=43.2; CBC14_DERV=213
SUBJECT_SAMPLE_FACTORS           	-	Plasma_69	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=97.3363; POST_FEV1FVC_DERV=0.8043818; SITE=MU164511; BMI_CM01=32.3; GENDER=1; RACE=1; AGE_DERV_01=49; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=None; CBC_NEUTROPHIL_CNT01=2.8; CBC_LYMPHOCYTE_CNT01=1.4; CBC_MONOCYTE_CNT01=0.4; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=30; BASELINE_ASTHMA_DX=-; CBC04_DERV=13.9; CBC05_DERV=40.5; CBC14_DERV=205
SUBJECT_SAMPLE_FACTORS           	-	Plasma_70	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=59.79393; POST_FEV1FVC_DERV=0.6562413; SITE=MU164604; BMI_CM01=25.3; GENDER=2; RACE=1; AGE_DERV_01=59; PEX_TOT0101=1; CB_VISIT1=-; CURRENT_SMOKER_V1=1; BRONCH_DIAGNOSED01=-; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=2.8; CBC_LYMPHOCYTE_CNT01=3.6; CBC_MONOCYTE_CNT01=0.6; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=44; BASELINE_ASTHMA_DX=-; CBC04_DERV=14; CBC05_DERV=40.5; CBC14_DERV=189
SUBJECT_SAMPLE_FACTORS           	-	Plasma_71	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=61.824097; POST_FEV1FVC_DERV=0.5211678; SITE=SF180395; BMI_CM01=23.5; GENDER=1; RACE=1; AGE_DERV_01=70; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=6.59; CBC_LYMPHOCYTE_CNT01=1.55; CBC_MONOCYTE_CNT01=0.74; CBC_EOSINOPHIL_CNT01=0.2; CBC_BASOPHIL_CNT01=0.05; SMOKING_PACK_YEARS01=25.5; BASELINE_ASTHMA_DX=-; CBC04_DERV=15.3; CBC05_DERV=45.9; CBC14_DERV=383
SUBJECT_SAMPLE_FACTORS           	-	Plasma_72	GOLD_STAGE_COPD_SEVERITY:1	PCT_POST_FEV1_V1=106.112816; POST_FEV1FVC_DERV=0.8476309; SITE=SF180449; BMI_CM01=19.3; GENDER=1; RACE=2; AGE_DERV_01=52; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=2.65; CBC_LYMPHOCYTE_CNT01=1.76; CBC_MONOCYTE_CNT01=0.34; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=0.05; SMOKING_PACK_YEARS01=-; BASELINE_ASTHMA_DX=-; CBC04_DERV=13.4; CBC05_DERV=40.3; CBC14_DERV=198
SUBJECT_SAMPLE_FACTORS           	-	Plasma_73	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=123.74261; POST_FEV1FVC_DERV=0.6855395; SITE=SF180454; BMI_CM01=33.6; GENDER=1; RACE=1; AGE_DERV_01=54; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=3.63; CBC_LYMPHOCYTE_CNT01=1.12; CBC_MONOCYTE_CNT01=0.41; CBC_EOSINOPHIL_CNT01=0.08; CBC_BASOPHIL_CNT01=0.02; SMOKING_PACK_YEARS01=20; BASELINE_ASTHMA_DX=-; CBC04_DERV=14; CBC05_DERV=41.7; CBC14_DERV=340
SUBJECT_SAMPLE_FACTORS           	-	Plasma_74	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=92.999275; POST_FEV1FVC_DERV=0.6461207; SITE=SF180555; BMI_CM01=29.3; GENDER=1; RACE=1; AGE_DERV_01=58; PEX_TOT0101=-; CB_VISIT1=1; CURRENT_SMOKER_V1=1; BRONCH_DIAGNOSED01=1; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=7.35; CBC_LYMPHOCYTE_CNT01=1.81; CBC_MONOCYTE_CNT01=0.32; CBC_EOSINOPHIL_CNT01=0.25; CBC_BASOPHIL_CNT01=0.03; SMOKING_PACK_YEARS01=52.5; BASELINE_ASTHMA_DX=-; CBC04_DERV=14.9; CBC05_DERV=43.9; CBC14_DERV=262
SUBJECT_SAMPLE_FACTORS           	-	Plasma_75	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=92.82619; POST_FEV1FVC_DERV=0.6943301; SITE=SF180588; BMI_CM01=37.1; GENDER=1; RACE=3; AGE_DERV_01=54; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=2; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=4.49; CBC_LYMPHOCYTE_CNT01=1.76; CBC_MONOCYTE_CNT01=0.39; CBC_EOSINOPHIL_CNT01=0.23; CBC_BASOPHIL_CNT01=0.05; SMOKING_PACK_YEARS01=33; BASELINE_ASTHMA_DX=-; CBC04_DERV=14.3; CBC05_DERV=42.4; CBC14_DERV=212
SUBJECT_SAMPLE_FACTORS           	-	Plasma_76	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=90.59619; POST_FEV1FVC_DERV=0.77748555; SITE=SF180642; BMI_CM01=32; GENDER=2; RACE=1; AGE_DERV_01=60; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=1; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=1.99; CBC_LYMPHOCYTE_CNT01=2.01; CBC_MONOCYTE_CNT01=0.3; CBC_EOSINOPHIL_CNT01=0.26; CBC_BASOPHIL_CNT01=0.01; SMOKING_PACK_YEARS01=37.5; BASELINE_ASTHMA_DX=-; CBC04_DERV=13.5; CBC05_DERV=39.4; CBC14_DERV=201
SUBJECT_SAMPLE_FACTORS           	-	Plasma_77	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=102.68633; POST_FEV1FVC_DERV=0.7316025; SITE=SF181428; BMI_CM01=25.3; GENDER=2; RACE=1; AGE_DERV_01=66; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=1; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=3.98; CBC_LYMPHOCYTE_CNT01=1.95; CBC_MONOCYTE_CNT01=0.27; CBC_EOSINOPHIL_CNT01=0.06; CBC_BASOPHIL_CNT01=0.01; SMOKING_PACK_YEARS01=86; BASELINE_ASTHMA_DX=-; CBC04_DERV=14.2; CBC05_DERV=42.2; CBC14_DERV=260
SUBJECT_SAMPLE_FACTORS           	-	Plasma_78	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=54.007626; POST_FEV1FVC_DERV=0.4563154; SITE=SF181665; BMI_CM01=34.3; GENDER=2; RACE=1; AGE_DERV_01=62; PEX_TOT0101=2; CB_VISIT1=1; CURRENT_SMOKER_V1=1; BRONCH_DIAGNOSED01=1; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=4.66; CBC_LYMPHOCYTE_CNT01=2.39; CBC_MONOCYTE_CNT01=0.59; CBC_EOSINOPHIL_CNT01=0.11; CBC_BASOPHIL_CNT01=0.02; SMOKING_PACK_YEARS01=90; BASELINE_ASTHMA_DX=1; CBC04_DERV=16.2; CBC05_DERV=48.9; CBC14_DERV=263
SUBJECT_SAMPLE_FACTORS           	-	Plasma_79	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=110.89107; POST_FEV1FVC_DERV=0.8788681; SITE=SF181786; BMI_CM01=21.9; GENDER=2; RACE=1; AGE_DERV_01=62; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=1; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=2.56; CBC_LYMPHOCYTE_CNT01=0.99; CBC_MONOCYTE_CNT01=0.25; CBC_EOSINOPHIL_CNT01=0.08; CBC_BASOPHIL_CNT01=0.02; SMOKING_PACK_YEARS01=30; BASELINE_ASTHMA_DX=-; CBC04_DERV=12.6; CBC05_DERV=37.7; CBC14_DERV=233
SUBJECT_SAMPLE_FACTORS           	-	Plasma_80	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=104.967705; POST_FEV1FVC_DERV=0.6114548; SITE=SF181819; BMI_CM01=29.1; GENDER=1; RACE=1; AGE_DERV_01=71; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=1; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=2.13; CBC_LYMPHOCYTE_CNT01=1.12; CBC_MONOCYTE_CNT01=0.38; CBC_EOSINOPHIL_CNT01=0.14; CBC_BASOPHIL_CNT01=0.01; SMOKING_PACK_YEARS01=117; BASELINE_ASTHMA_DX=-; CBC04_DERV=15.8; CBC05_DERV=46.3; CBC14_DERV=149
SUBJECT_SAMPLE_FACTORS           	-	Plasma_81	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=117.52982; POST_FEV1FVC_DERV=0.8578094; SITE=SF182197; BMI_CM01=25.6; GENDER=2; RACE=1; AGE_DERV_01=57; PEX_TOT0101=-; CB_VISIT1=1; CURRENT_SMOKER_V1=1; BRONCH_DIAGNOSED01=1; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=6.39; CBC_LYMPHOCYTE_CNT01=1.17; CBC_MONOCYTE_CNT01=0.45; CBC_EOSINOPHIL_CNT01=0.15; CBC_BASOPHIL_CNT01=0.03; SMOKING_PACK_YEARS01=31.5; BASELINE_ASTHMA_DX=-; CBC04_DERV=13.8; CBC05_DERV=39.2; CBC14_DERV=230
SUBJECT_SAMPLE_FACTORS           	-	Plasma_82	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=73.013695; POST_FEV1FVC_DERV=0.5739645; SITE=SF182699; BMI_CM01=31; GENDER=1; RACE=1; AGE_DERV_01=66; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=3.52; CBC_LYMPHOCYTE_CNT01=1.52; CBC_MONOCYTE_CNT01=0.56; CBC_EOSINOPHIL_CNT01=0.25; CBC_BASOPHIL_CNT01=0.04; SMOKING_PACK_YEARS01=67.5; BASELINE_ASTHMA_DX=-; CBC04_DERV=15.9; CBC05_DERV=46; CBC14_DERV=114
SUBJECT_SAMPLE_FACTORS           	-	Plasma_83	GOLD_STAGE_COPD_SEVERITY:1	PCT_POST_FEV1_V1=97.17778; POST_FEV1FVC_DERV=0.74140036; SITE=SF183103; BMI_CM01=25.9; GENDER=1; RACE=1; AGE_DERV_01=68; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=3.21; CBC_LYMPHOCYTE_CNT01=1.15; CBC_MONOCYTE_CNT01=0.38; CBC_EOSINOPHIL_CNT01=0.09; CBC_BASOPHIL_CNT01=0.05; SMOKING_PACK_YEARS01=-; BASELINE_ASTHMA_DX=-; CBC04_DERV=14.7; CBC05_DERV=43.7; CBC14_DERV=191
SUBJECT_SAMPLE_FACTORS           	-	Plasma_84	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=89.21391; POST_FEV1FVC_DERV=0.6744577; SITE=SF183215; BMI_CM01=33.7; GENDER=1; RACE=1; AGE_DERV_01=46; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=1; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=4.58; CBC_LYMPHOCYTE_CNT01=1.69; CBC_MONOCYTE_CNT01=0.43; CBC_EOSINOPHIL_CNT01=0.09; CBC_BASOPHIL_CNT01=0.03; SMOKING_PACK_YEARS01=40; BASELINE_ASTHMA_DX=1; CBC04_DERV=14.3; CBC05_DERV=42.5; CBC14_DERV=238
SUBJECT_SAMPLE_FACTORS           	-	Plasma_85	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=110.84914; POST_FEV1FVC_DERV=0.68444234; SITE=SF183333; BMI_CM01=32.3; GENDER=1; RACE=2; AGE_DERV_01=59; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=1; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=4.73; CBC_LYMPHOCYTE_CNT01=1.97; CBC_MONOCYTE_CNT01=0.44; CBC_EOSINOPHIL_CNT01=0.4; CBC_BASOPHIL_CNT01=0.08; SMOKING_PACK_YEARS01=40; BASELINE_ASTHMA_DX=-; CBC04_DERV=15.4; CBC05_DERV=44.3; CBC14_DERV=257
SUBJECT_SAMPLE_FACTORS           	-	Plasma_86	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=87.55967; POST_FEV1FVC_DERV=0.6654265; SITE=SF183340; BMI_CM01=34.6; GENDER=2; RACE=1; AGE_DERV_01=50; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=1; BRONCH_DIAGNOSED01=-; MENOPAUSE01=No; CBC_NEUTROPHIL_CNT01=3.58; CBC_LYMPHOCYTE_CNT01=3.38; CBC_MONOCYTE_CNT01=0.76; CBC_EOSINOPHIL_CNT01=0.18; CBC_BASOPHIL_CNT01=0.05; SMOKING_PACK_YEARS01=45; BASELINE_ASTHMA_DX=1; CBC04_DERV=12.7; CBC05_DERV=38.1; CBC14_DERV=258
SUBJECT_SAMPLE_FACTORS           	-	Plasma_87	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=99.113266; POST_FEV1FVC_DERV=0.77454275; SITE=SF183431; BMI_CM01=24; GENDER=1; RACE=1; AGE_DERV_01=56; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=1; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=5.96; CBC_LYMPHOCYTE_CNT01=2.62; CBC_MONOCYTE_CNT01=0.58; CBC_EOSINOPHIL_CNT01=0.14; CBC_BASOPHIL_CNT01=0.05; SMOKING_PACK_YEARS01=40; BASELINE_ASTHMA_DX=-; CBC04_DERV=14; CBC05_DERV=40.6; CBC14_DERV=268
SUBJECT_SAMPLE_FACTORS           	-	Plasma_89	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=79.729866; POST_FEV1FVC_DERV=0.6059006; SITE=UT170054; BMI_CM01=32.8; GENDER=1; RACE=1; AGE_DERV_01=74; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=3.4; CBC_LYMPHOCYTE_CNT01=1.9; CBC_MONOCYTE_CNT01=0.4; CBC_EOSINOPHIL_CNT01=0.3; CBC_BASOPHIL_CNT01=0.1; SMOKING_PACK_YEARS01=62; BASELINE_ASTHMA_DX=-; CBC04_DERV=14; CBC05_DERV=41.9; CBC14_DERV=235
SUBJECT_SAMPLE_FACTORS           	-	Plasma_90	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=67.11058; POST_FEV1FVC_DERV=0.483271; SITE=UT170148; BMI_CM01=25.5; GENDER=1; RACE=1; AGE_DERV_01=56; PEX_TOT0101=2; CB_VISIT1=-; CURRENT_SMOKER_V1=1; BRONCH_DIAGNOSED01=NA; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=4.7; CBC_LYMPHOCYTE_CNT01=2.3; CBC_MONOCYTE_CNT01=0.7; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=0.2; SMOKING_PACK_YEARS01=42; BASELINE_ASTHMA_DX=1; CBC04_DERV=17.7; CBC05_DERV=53.5; CBC14_DERV=285
SUBJECT_SAMPLE_FACTORS           	-	Plasma_91	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=59.71983; POST_FEV1FVC_DERV=0.8204888; SITE=UT170364; BMI_CM01=24.1; GENDER=2; RACE=1; AGE_DERV_01=63; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=1; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=2.9; CBC_LYMPHOCYTE_CNT01=1.4; CBC_MONOCYTE_CNT01=0.3; CBC_EOSINOPHIL_CNT01=0.2; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=30; BASELINE_ASTHMA_DX=-; CBC04_DERV=13.5; CBC05_DERV=40.6; CBC14_DERV=335
SUBJECT_SAMPLE_FACTORS           	-	Plasma_92	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=92.65662; POST_FEV1FVC_DERV=0.68763024; SITE=UT170416; BMI_CM01=22.3; GENDER=1; RACE=1; AGE_DERV_01=71; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=5.3; CBC_LYMPHOCYTE_CNT01=2.1; CBC_MONOCYTE_CNT01=0.6; CBC_EOSINOPHIL_CNT01=0.2; CBC_BASOPHIL_CNT01=0.1; SMOKING_PACK_YEARS01=30; BASELINE_ASTHMA_DX=-; CBC04_DERV=14; CBC05_DERV=42.6; CBC14_DERV=NA
SUBJECT_SAMPLE_FACTORS           	-	Plasma_93	GOLD_STAGE_COPD_SEVERITY:1	PCT_POST_FEV1_V1=88.9345; POST_FEV1FVC_DERV=0.7693505; SITE=UT171714; BMI_CM01=24.8; GENDER=1; RACE=7; AGE_DERV_01=56; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=3.6; CBC_LYMPHOCYTE_CNT01=2.5; CBC_MONOCYTE_CNT01=0.4; CBC_EOSINOPHIL_CNT01=0.2; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=-; BASELINE_ASTHMA_DX=-; CBC04_DERV=15.8; CBC05_DERV=45.9; CBC14_DERV=298
SUBJECT_SAMPLE_FACTORS           	-	Plasma_94	GOLD_STAGE_COPD_SEVERITY:1	PCT_POST_FEV1_V1=96.67955; POST_FEV1FVC_DERV=0.721411; SITE=UT171775; BMI_CM01=24.6; GENDER=1; RACE=1; AGE_DERV_01=60; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=3.3; CBC_LYMPHOCYTE_CNT01=1.2; CBC_MONOCYTE_CNT01=0.3; CBC_EOSINOPHIL_CNT01=0.3; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=-; BASELINE_ASTHMA_DX=-; CBC04_DERV=15.8; CBC05_DERV=48.7; CBC14_DERV=231
SUBJECT_SAMPLE_FACTORS           	-	Plasma_95	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=65.66856; POST_FEV1FVC_DERV=0.6008532; SITE=UT171824; BMI_CM01=33.8; GENDER=1; RACE=1; AGE_DERV_01=59; PEX_TOT0101=-; CB_VISIT1=1; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=NA; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=3.4; CBC_LYMPHOCYTE_CNT01=2; CBC_MONOCYTE_CNT01=0.4; CBC_EOSINOPHIL_CNT01=0.2; CBC_BASOPHIL_CNT01=0.1; SMOKING_PACK_YEARS01=82; BASELINE_ASTHMA_DX=NA; CBC04_DERV=15.6; CBC05_DERV=46.1; CBC14_DERV=220
SUBJECT_SAMPLE_FACTORS           	-	Plasma_96	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=82.0503; POST_FEV1FVC_DERV=0.67621344; SITE=UT172346; BMI_CM01=30.2; GENDER=2; RACE=1; AGE_DERV_01=61; PEX_TOT0101=1; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=4.6; CBC_LYMPHOCYTE_CNT01=1.6; CBC_MONOCYTE_CNT01=0.3; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=36; BASELINE_ASTHMA_DX=-; CBC04_DERV=14; CBC05_DERV=42.2; CBC14_DERV=364
SUBJECT_SAMPLE_FACTORS           	-	Plasma_97	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=82.72565; POST_FEV1FVC_DERV=0.7502791; SITE=UT172465; BMI_CM01=24.5; GENDER=1; RACE=1; AGE_DERV_01=64; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=5.7; CBC_LYMPHOCYTE_CNT01=1.1; CBC_MONOCYTE_CNT01=0.3; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=45; BASELINE_ASTHMA_DX=-; CBC04_DERV=16.7; CBC05_DERV=47.4; CBC14_DERV=224
SUBJECT_SAMPLE_FACTORS           	-	Plasma_99	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=107.49941; POST_FEV1FVC_DERV=0.8026749; SITE=UT172506; BMI_CM01=31.3; GENDER=2; RACE=1; AGE_DERV_01=57; PEX_TOT0101=1; CB_VISIT1=1; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=1; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=5.9; CBC_LYMPHOCYTE_CNT01=3; CBC_MONOCYTE_CNT01=0.4; CBC_EOSINOPHIL_CNT01=-; CBC_BASOPHIL_CNT01=0.1; SMOKING_PACK_YEARS01=38; BASELINE_ASTHMA_DX=-; CBC04_DERV=16; CBC05_DERV=47.6; CBC14_DERV=234
SUBJECT_SAMPLE_FACTORS           	-	Plasma_100	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=119.94436; POST_FEV1FVC_DERV=0.7959028; SITE=UT172527; BMI_CM01=24.9; GENDER=2; RACE=1; AGE_DERV_01=48; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=NA; MENOPAUSE01=Unknown; CBC_NEUTROPHIL_CNT01=3; CBC_LYMPHOCYTE_CNT01=1.4; CBC_MONOCYTE_CNT01=0.3; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=0.1; SMOKING_PACK_YEARS01=60; BASELINE_ASTHMA_DX=1; CBC04_DERV=15; CBC05_DERV=44.3; CBC14_DERV=180
SUBJECT_SAMPLE_FACTORS           	-	Plasma_101	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=113.734184; POST_FEV1FVC_DERV=0.8063443; SITE=UT172630; BMI_CM01=25.3; GENDER=1; RACE=1; AGE_DERV_01=42; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=1; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=3.9; CBC_LYMPHOCYTE_CNT01=2.3; CBC_MONOCYTE_CNT01=0.4; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=23; BASELINE_ASTHMA_DX=-; CBC04_DERV=15.4; CBC05_DERV=45.2; CBC14_DERV=332
SUBJECT_SAMPLE_FACTORS           	-	Plasma_102	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=74.32744; POST_FEV1FVC_DERV=0.62112546; SITE=UT172747; BMI_CM01=26.8; GENDER=1; RACE=1; AGE_DERV_01=51; PEX_TOT0101=1; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=NA; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=2.9; CBC_LYMPHOCYTE_CNT01=0.9; CBC_MONOCYTE_CNT01=0.3; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=37.5; BASELINE_ASTHMA_DX=NA; CBC04_DERV=15.2; CBC05_DERV=46.8; CBC14_DERV=117
SUBJECT_SAMPLE_FACTORS           	-	Plasma_103	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=87.999176; POST_FEV1FVC_DERV=0.72673655; SITE=UT172812; BMI_CM01=20.6; GENDER=2; RACE=1; AGE_DERV_01=46; PEX_TOT0101=2; CB_VISIT1=1; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=1; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=5.3; CBC_LYMPHOCYTE_CNT01=4.1; CBC_MONOCYTE_CNT01=0.3; CBC_EOSINOPHIL_CNT01=-; CBC_BASOPHIL_CNT01=0.1; SMOKING_PACK_YEARS01=60; BASELINE_ASTHMA_DX=-; CBC04_DERV=14.1; CBC05_DERV=42.7; CBC14_DERV=197
SUBJECT_SAMPLE_FACTORS           	-	Plasma_104	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=133.00407; POST_FEV1FVC_DERV=0.80093795; SITE=UT173192; BMI_CM01=26.2; GENDER=1; RACE=1; AGE_DERV_01=52; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=3.7; CBC_LYMPHOCYTE_CNT01=1.7; CBC_MONOCYTE_CNT01=0.7; CBC_EOSINOPHIL_CNT01=0.2; CBC_BASOPHIL_CNT01=0.1; SMOKING_PACK_YEARS01=37; BASELINE_ASTHMA_DX=-; CBC04_DERV=14.4; CBC05_DERV=43.2; CBC14_DERV=258
SUBJECT_SAMPLE_FACTORS           	-	Plasma_105	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=74.39527; POST_FEV1FVC_DERV=0.6888036; SITE=UT173301; BMI_CM01=24.2; GENDER=1; RACE=1; AGE_DERV_01=54; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=1; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=6.2; CBC_LYMPHOCYTE_CNT01=2.1; CBC_MONOCYTE_CNT01=0.4; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=0.1; SMOKING_PACK_YEARS01=50; BASELINE_ASTHMA_DX=-; CBC04_DERV=16.2; CBC05_DERV=47.3; CBC14_DERV=230
SUBJECT_SAMPLE_FACTORS           	-	Plasma_106	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=118.230316; POST_FEV1FVC_DERV=0.73151183; SITE=UT173617; BMI_CM01=25.2; GENDER=1; RACE=1; AGE_DERV_01=60; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=1; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=4.2; CBC_LYMPHOCYTE_CNT01=1.7; CBC_MONOCYTE_CNT01=0.4; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=40; BASELINE_ASTHMA_DX=-; CBC04_DERV=14.9; CBC05_DERV=44.5; CBC14_DERV=276
SUBJECT_SAMPLE_FACTORS           	-	Plasma_107	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=116.40028; POST_FEV1FVC_DERV=0.747785; SITE=UT174002; BMI_CM01=22.9; GENDER=1; RACE=1; AGE_DERV_01=51; PEX_TOT0101=-; CB_VISIT1=1; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=1; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=6.2; CBC_LYMPHOCYTE_CNT01=1.6; CBC_MONOCYTE_CNT01=0.6; CBC_EOSINOPHIL_CNT01=-; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=23; BASELINE_ASTHMA_DX=-; CBC04_DERV=17.5; CBC05_DERV=51.2; CBC14_DERV=245
SUBJECT_SAMPLE_FACTORS           	-	Plasma_108	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=70.60119; POST_FEV1FVC_DERV=0.61541057; SITE=UT174372; BMI_CM01=25.5; GENDER=2; RACE=1; AGE_DERV_01=57; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=1; BRONCH_DIAGNOSED01=-; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=4.1; CBC_LYMPHOCYTE_CNT01=1.8; CBC_MONOCYTE_CNT01=0.4; CBC_EOSINOPHIL_CNT01=0.5; CBC_BASOPHIL_CNT01=0.1; SMOKING_PACK_YEARS01=60; BASELINE_ASTHMA_DX=-; CBC04_DERV=14.6; CBC05_DERV=44; CBC14_DERV=414
SUBJECT_SAMPLE_FACTORS           	-	Plasma_109	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=117.25666; POST_FEV1FVC_DERV=0.7920792; SITE=WF122105; BMI_CM01=27.5; GENDER=2; RACE=1; AGE_DERV_01=74; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=3; CBC_LYMPHOCYTE_CNT01=1.4; CBC_MONOCYTE_CNT01=0.3; CBC_EOSINOPHIL_CNT01=0.2; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=35; BASELINE_ASTHMA_DX=-; CBC04_DERV=14.1; CBC05_DERV=40.7; CBC14_DERV=222
SUBJECT_SAMPLE_FACTORS           	-	Plasma_110	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=86.742584; POST_FEV1FVC_DERV=0.7036816; SITE=WF122736; BMI_CM01=21.7; GENDER=2; RACE=1; AGE_DERV_01=71; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=NA; BRONCH_DIAGNOSED01=-; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=3; CBC_LYMPHOCYTE_CNT01=1.3; CBC_MONOCYTE_CNT01=0.3; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=46; BASELINE_ASTHMA_DX=-; CBC04_DERV=14; CBC05_DERV=42.3; CBC14_DERV=198
SUBJECT_SAMPLE_FACTORS           	-	Plasma_111	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=49.94717; POST_FEV1FVC_DERV=0.5951694; SITE=WF122906; BMI_CM01=24.6; GENDER=1; RACE=1; AGE_DERV_01=50; PEX_TOT0101=1; CB_VISIT1=1; CURRENT_SMOKER_V1=-; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=5.4; CBC_LYMPHOCYTE_CNT01=1.9; CBC_MONOCYTE_CNT01=0.4; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=80; BASELINE_ASTHMA_DX=-; CBC04_DERV=14.1; CBC05_DERV=43.5; CBC14_DERV=229
SUBJECT_SAMPLE_FACTORS           	-	Plasma_112	GOLD_STAGE_COPD_SEVERITY:3	PCT_POST_FEV1_V1=79.59453; POST_FEV1FVC_DERV=0.5925124; SITE=WF123618; BMI_CM01=32.7; GENDER=1; RACE=1; AGE_DERV_01=65; PEX_TOT0101=1; CB_VISIT1=-; CURRENT_SMOKER_V1=NA; BRONCH_DIAGNOSED01=NA; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=4.1; CBC_LYMPHOCYTE_CNT01=1.2; CBC_MONOCYTE_CNT01=0.5; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=37.5; BASELINE_ASTHMA_DX=-; CBC04_DERV=15.2; CBC05_DERV=45.8; CBC14_DERV=246
SUBJECT_SAMPLE_FACTORS           	-	Plasma_113	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=83.78584; POST_FEV1FVC_DERV=0.77412665; SITE=WF123897; BMI_CM01=29.1; GENDER=2; RACE=1; AGE_DERV_01=67; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=NA; BRONCH_DIAGNOSED01=1; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=4.2; CBC_LYMPHOCYTE_CNT01=1.7; CBC_MONOCYTE_CNT01=0.4; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=21; BASELINE_ASTHMA_DX=-; CBC04_DERV=12.9; CBC05_DERV=40; CBC14_DERV=235
SUBJECT_SAMPLE_FACTORS           	-	Plasma_114	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=90.76917; POST_FEV1FVC_DERV=0.77926046; SITE=WF124216; BMI_CM01=32.7; GENDER=1; RACE=1; AGE_DERV_01=66; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=NA; BRONCH_DIAGNOSED01=-; MENOPAUSE01=NA; CBC_NEUTROPHIL_CNT01=4.4; CBC_LYMPHOCYTE_CNT01=2.3; CBC_MONOCYTE_CNT01=0.7; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=49; BASELINE_ASTHMA_DX=-; CBC04_DERV=16.8; CBC05_DERV=51.2; CBC14_DERV=183
SUBJECT_SAMPLE_FACTORS           	-	Plasma_115	GOLD_STAGE_COPD_SEVERITY:1	PCT_POST_FEV1_V1=107.0152; POST_FEV1FVC_DERV=0.767411; SITE=WF124819; BMI_CM01=21.3; GENDER=2; RACE=1; AGE_DERV_01=57; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=NA; BRONCH_DIAGNOSED01=-; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=2.8; CBC_LYMPHOCYTE_CNT01=1.1; CBC_MONOCYTE_CNT01=0.5; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=-; BASELINE_ASTHMA_DX=-; CBC04_DERV=12.9; CBC05_DERV=39.8; CBC14_DERV=259
SUBJECT_SAMPLE_FACTORS           	-	Plasma_116	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=78.84307; POST_FEV1FVC_DERV=0.7421897; SITE=WF124946; BMI_CM01=29.9; GENDER=2; RACE=1; AGE_DERV_01=57; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=NA; BRONCH_DIAGNOSED01=1; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=11.4; CBC_LYMPHOCYTE_CNT01=4.7; CBC_MONOCYTE_CNT01=1.5; CBC_EOSINOPHIL_CNT01=0.6; CBC_BASOPHIL_CNT01=0.1; SMOKING_PACK_YEARS01=23.5; BASELINE_ASTHMA_DX=-; CBC04_DERV=16.6; CBC05_DERV=51.9; CBC14_DERV=291
SUBJECT_SAMPLE_FACTORS           	-	Plasma_117	GOLD_STAGE_COPD_SEVERITY:2	PCT_POST_FEV1_V1=98.97721; POST_FEV1FVC_DERV=0.75391155; SITE=WF125136; BMI_CM01=26.6; GENDER=2; RACE=1; AGE_DERV_01=66; PEX_TOT0101=-; CB_VISIT1=-; CURRENT_SMOKER_V1=NA; BRONCH_DIAGNOSED01=1; MENOPAUSE01=Yes; CBC_NEUTROPHIL_CNT01=2.1; CBC_LYMPHOCYTE_CNT01=2.1; CBC_MONOCYTE_CNT01=0.4; CBC_EOSINOPHIL_CNT01=0.1; CBC_BASOPHIL_CNT01=-; SMOKING_PACK_YEARS01=34.5; BASELINE_ASTHMA_DX=2; CBC04_DERV=14.2; CBC05_DERV=41.6; CBC14_DERV=234
#COLLECTION
CO:COLLECTION_SUMMARY            	Blood is drawn into a 10 ml heparin plasma tube, and immediately sent to the
CO:COLLECTION_SUMMARY            	medical center clinical laboratory for further processing.
CO:SAMPLE_TYPE                   	Blood (plasma)
CO:STORAGE_CONDITIONS            	-80℃
#TREATMENT
TR:TREATMENT_SUMMARY             	N/A
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	Plasma samples were thawed and 100 uL was prepared using methanol precipitation
SP:SAMPLEPREP_SUMMARY            	and liquid-liquid extraction as previously described (PMCID PMC4214365, PMCID
SP:SAMPLEPREP_SUMMARY            	PMC3734953) . In short, following the addition of standards, 400uL of ice cold
SP:SAMPLEPREP_SUMMARY            	MeOH was added to 100uL of plasma to precipitate proteins, then vortexed for 10
SP:SAMPLEPREP_SUMMARY            	seconds, and centrifgued at 0oC for 15 min at 18,000 rpm to pellet precipitated
SP:SAMPLEPREP_SUMMARY            	protein. The supernatant was transferred to a glass culture tube and dried under
SP:SAMPLEPREP_SUMMARY            	N2. 3.1mL MTBE was added to the dried methanol residue, vortexed for 30 seconds,
SP:SAMPLEPREP_SUMMARY            	750uL of water added to the tube, and vortex 10 seconds. The sample was then
SP:SAMPLEPREP_SUMMARY            	spun at 1000 rpm for 10 min at RT to form bilayer. 2.5 mL of MTBE layer was
SP:SAMPLEPREP_SUMMARY            	aliquoted and transferred to a new, clean glass culture tube. Then 3.0 mL MTBE
SP:SAMPLEPREP_SUMMARY            	was added to remaining water layer of sample, vortexed for 10 seconds, and
SP:SAMPLEPREP_SUMMARY            	centrifuged at 200 x g for 10 min at RT to form bilayer. 3mL of MTBE was
SP:SAMPLEPREP_SUMMARY            	aliquoted and combined with previous MTBE tube. This MTBE layer was dried under
SP:SAMPLEPREP_SUMMARY            	nitrogen at 35oC, and quickly re-suspend in 200uL Methanol, vortexed for 5
SP:SAMPLEPREP_SUMMARY            	seconds and transfered to glass autosampler vial. The aqueous layer was dried
SP:SAMPLEPREP_SUMMARY            	under N2, 100uL of water quickly added to minimize oxidation. Then 400uL of ice
SP:SAMPLEPREP_SUMMARY            	cold MeOH was added, vortexed for 10 seconds, transfered to a 1.5 ml low
SP:SAMPLEPREP_SUMMARY            	retention Fisher microtube and frozen at -80oC for 25 min to crash out any
SP:SAMPLEPREP_SUMMARY            	remaining residual proteins. Then centrifuged at 0oC for 15 min at 18,000 xg.
SP:SAMPLEPREP_SUMMARY            	The supernatant was transferred to a clean microtube, dried in speed vac at
SP:SAMPLEPREP_SUMMARY            	45oC. The dried supernatant was quickly resuspended in 100uL of 5% ACN in water,
SP:SAMPLEPREP_SUMMARY            	vortexed for 30 sec, then transferred to autosampler vials, and stored at -80C
SP:SAMPLEPREP_SUMMARY            	prior to MS analysis.
SP:PROCESSING_STORAGE_CONDITIONS 	Described in summary
SP:EXTRACT_STORAGE               	Described in summary
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_SUMMARY        	The samples from the aqueous small molecule fraction were analyzed randomly in
CH:CHROMATOGRAPHY_SUMMARY        	triplicate using an Agilent 1290 series pump using a Phenomenex Kinetex HILIC,
CH:CHROMATOGRAPHY_SUMMARY        	2.6 µm, 100 Å (2.1 × 50 mm) analytical column and an Agilent Zorbax Eclipse
CH:CHROMATOGRAPHY_SUMMARY        	Plus-C8 5 µm (2.1 × 12.5 mm) narrow bore guard column. The autosampler tray
CH:CHROMATOGRAPHY_SUMMARY        	temperature was set at 4 °C, column temperature was set at 20 °C, and the
CH:CHROMATOGRAPHY_SUMMARY        	sample injection volume was 1 µL for both BAL and plasma. The flow rate of 0.6
CH:CHROMATOGRAPHY_SUMMARY        	mL/min with the following mobile phases: mobile phase A was 50% ACN with pH 5.8
CH:CHROMATOGRAPHY_SUMMARY        	ammonium acetate, and mobile phase B was 90% ACN with pH 5.8 ammonium acetate.
CH:CHROMATOGRAPHY_SUMMARY        	Gradient elution was as follows: 0.2 minutes 100% B, 0.2–2.1 minutes 100–90%
CH:CHROMATOGRAPHY_SUMMARY        	B, 2.1–8.6 minutes 90–50% B, 8.6–8.7 minutes 50–0% B, 8.7–14.7 minutes
CH:CHROMATOGRAPHY_SUMMARY        	0% B, 14.7–14.8 minutes 0–100% B, 14.8–24.8 minutes 100% B.
CH:CHROMATOGRAPHY_TYPE           	Normal phase
CH:INSTRUMENT_NAME               	Agilent 6520
CH:COLUMN_NAME                   	Phenomenex Kinetex HILIC 100A (50 x 2.1 mm, 2.6um)
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
#MS
MS:INSTRUMENT_NAME               	Agilent 6520 QTOF
MS:INSTRUMENT_TYPE               	QTOF
MS:MS_TYPE                       	ESI
MS:ION_MODE                      	POSITIVE
MS:MS_COMMENTS                   	Agilent 6520 QTOF-MS in positive ionization mode with dual ESI source, mass
MS:MS_COMMENTS                   	range 50–1700 m/z, scan rate 2.00, gas temperature 325 °C, gas flow 12.0
MS:MS_COMMENTS                   	L/min, nebulizer 30 psi, skimmer 60 V, capillary voltage 4000 V, fragmentor 120
MS:MS_COMMENTS                   	V, reference masses 121.050873 and 922.009798 (Agilent reference mix). The
MS:MS_COMMENTS                   	analysis was replicated for tandem MS of selected compounds using a scan range
MS:MS_COMMENTS                   	50–1700m/z, and 10, 20, and 40 eV collision energies with a 500 ms/spectra
MS:MS_COMMENTS                   	acquisition time, 1.3 m/z (narrow) isolation width, and 0.25 minute delta
MS:MS_COMMENTS                   	retention time.
MS:MS_RESULTS_FILE               	ST001217_AN002030_Results.txt	UNITS:Abundance (Log2)	Has m/z:Neutral masses	Has RT:Yes	RT units:Minutes
#END